Category Archives: Lamictal

Featured Stories

Federal DePuy ASR Hip Implant Trials Likely to Start This Year

It looks as though the first trials in the DePuy ASR hip implant multidistrict litigation could begin sometime later this year. According to a report from Bloomberg News, during a status conference held yesterday in Florida, attorneys for both plaintiffs and the defense told U.S. District Judge David Katz that ...

Read More

Medtronic Plans Layoffs, as Infuse Bone Graft Controversy Continues to Weigh on Spinal Business

Medtronic’s spinal division continues to take a huge hit thanks to the controversy surrounding its Infuse Bone Graft product. According to a report from MassDevice.com, the company’s latest earnings report stated that the division saw Infuse sales decline 26% in the first quarter of 2012, and now Medtronic is talking ...

Read More

Study Linking Z-Pak to Increased Death Risk Being Reviewed by FDA

The U.S. Food & Drug Administration (FDA) is reviewing a new study that reported an increased risk of sudden, heart-related deaths among people using the antibiotic Zithromax (azithromycin), known popularly as Z-Pak. In a statement issued late yesterday, the FDA said patients being treated with Zithromax should not stop taking ...

Read More

Lawsuit Alleges Plavix Caused Oklahoma Man to Suffer Multiple Stomach Bleeds

Another lawsuit has been filed over adverse Plavix side effects. The lawsuit, filed by national law firm Parker Waichman LLP, alleges that the blood thinner, Plavix (clopidogrel), caused an Oklahoma man to suffer from multiple stomach bleeds.

Read More

Medtronic Infuse Lawsuit Alleges Off-Label Use Cause Painful Complications

A man in Louisiana has filed suit against Medtronic Inc. over injuries allegedly cause by off-label use of its Infuse Bone Graft product. The plaintiff, who received Infuse during transforaminal spinal lumbar fusion surgery, claims that the bone growth protein caused unwanted bone growth along his spine, worsening the back ...

Read More

West Virginia Man Claims Metal-on-Metal DePuy Pinnacle Hip Replacement Led to Pain, Elevated Cobalt Levels

A West Virginia man fitted with a metal-on-metal version of DePuy Orthopaedics’ Pinnacle Hip Implant System has filed suit against the company and its parent, Johnson & Johnson, alleging the device caused him to suffer pain and elevated cobalt levels. The Plaintiff is being represented by the national law ...

Read More

FDA Panel Takes up Metal-on-Metal Hip Implant Safety Today

The Food and Drug Administration (FDA) is convening a meeting starting today to help decide the future of metal-on-metal hip implants following high-profile recalls and mounting questions about their overall safety.

Read More

FDA Gives 7 Companies Go Ahead To Market Generic Plavix

The U.S. Food & Drug Administration (FDA) just gave seven companies the go-ahead to market generic Plavix. Plavix is a blood thinner prescribed for the prevention of blood clots, heart attacks, and which has been linked to serious side effects such as the heart attacks and strokes it is supposed to ...

Read More

Dilantin Linked to Stevens-Johnson Syndrome, a Dangerous Skin Condition

Dilantin Linked to Stevens-Johnson Syndrome

Dilantin, the anti-epileptic drug that has been in use for decades is one of many drugs associated with the related skin conditions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Though these conditions are rare, when they do occur they … Continue reading

Posted in Acetaminophen / Tylenol, Dilantin, Health Concerns, Lamictal, Pharmaceuticals, Zithromax | Tagged , , , , |

Australian Teenager Suffers Severe Skin Reaction to Epilepsy Medication

An Australian teenage girl almost died on her birthday after suffering a serious toxic skin reaction to her epilepsy medications. Danika Heron’s skin began to burn from the inside out, after the new epilepsy medicine she was prescribed triggered two … Continue reading

Posted in Health Concerns, Keppra, Lamictal, Pharmaceuticals |

Keppra, Lamictal May Birth Defect Risks Possibly Higher Than Thought

A non-profit group believes two epilepsy drugs should be reclassified by federal regulators to indicate their risk of birth defects if they’re taken by pregnant women. According to a statement from AdverseEvents Inc., the epilepsy drugs Keppra and Lamictal should … Continue reading

Posted in Keppra, Lamictal, Legal News |

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.